265 related articles for article (PubMed ID: 12468176)
1. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J
Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176
[TBL] [Abstract][Full Text] [Related]
2. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas.
Yalta T; Atay L; Atalay F; Caydere M; Gonultas M; Ustun H
J Int Med Res; 2009; 37(1):163-8. PubMed ID: 19215686
[TBL] [Abstract][Full Text] [Related]
6. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
7. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
8. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression in papillary serous endometrial carcinoma.
Hosford S; Elliott J; Ma ZW; Majeste R; Dubeshter B
Int J Gynecol Cancer; 2003; 13(4):480-4. PubMed ID: 12911725
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.
Martinez AA; Weiner S; Podratz K; Armin AR; Stromberg JS; Stanhope R; Sherman A; Schray M; Brabbins DA
Gynecol Oncol; 2003 Sep; 90(3):537-46. PubMed ID: 13678721
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
[TBL] [Abstract][Full Text] [Related]
13. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.
Matthews RP; Hutchinson-Colas J; Maiman M; Fruchter RG; Gates EJ; Gibbon D; Remy JC; Sedlis A
Gynecol Oncol; 1997 May; 65(2):206-12. PubMed ID: 9159326
[TBL] [Abstract][Full Text] [Related]
14. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
15. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
16. Pathological findings in early-stage endometrial cancer.
Zehavi S; Schneider D; Bukovsky I; Halperin R
Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
[TBL] [Abstract][Full Text] [Related]
17. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
18. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications.
Aquino-Parsons C; Lim P; Wong F; Mildenberger M
Gynecol Oncol; 1998 Oct; 71(1):83-6. PubMed ID: 9784324
[TBL] [Abstract][Full Text] [Related]
19. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
20. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
